従来型, 生物学的, 合成分子標的抗リウマチ薬で治療中の関節リウマ患者の主要心血管イベント: ドイツRABBIT レジストリからの観察研究

RMD Open 2023;9:e003489 doi 10.1136/rmdopen-2023-003489

This study by Meissner, et al. estimated the effects of JAKi, TNFi, bDMARDs and csDMARDs on the risk of MACE in RA patients. The authors found no significant difference in MACE risk by treatment group, even among patients at increased CV risk.

This cohort study analysed episodes of RA treatments initiated between January 2017 and April 2022 in the RABBIT register. MACE incidence rates and HRs were calculated for the overall patient cohort and for the increased CV risk subgroup.

Keywords:


Publication thumbnail: 従来型, 生物学的, 合成分子標的抗リウマチ薬で治療中の関節リウマ患者の主要心血管イベント: ドイツRABBIT レジストリからの観察研究
LinkedIn